trans-1,2-Diaminocyclohexane-N,N,N',N'-tetraacetic acid monohydrate
CAS: 125572-95-4
Ref. 3D-FD15679
1kg | 1,033.00 € | ||
50g | 156.00 € | ||
100g | 217.00 € | ||
250g | 406.00 € | ||
500g | 588.00 € |
Product Information
- CDTA monohydrate1,2-Cyclohexylenedinitrilotetraacetic acid monohydrate
- 2,2',2'',2'''-[(1R,2R)-cyclohexane-1,2-diyldiammonio]tetraacetate monohydrate
- 2,2',2'',2'''-[(1R,2R)-cyclohexane-1,2-diyldinitrilo]tetraacetic acid hydrate
- 2,2',2'',2'''-[(1S,2S)-Cyclohexane-1,2-diyldinitrilo]tetraacetic acid monohydrate
- Glycine, N,N′-(1R,2R)-1,2-cyclohexanediylbis[N-(carboxymethyl)-, hydrate (1:1), rel-
- Glycine, N,N′-(1R,2R)-1,2-cyclohexanediylbis[N-(carboxymethyl)-, monohydrate, rel-
- Glycine, N,N′-1,2-cyclohexanediylbis[N-(carboxymethyl)-, monohydrate, trans-(±)-
- rel-N,N′-(1R,2R)-1,2-Cyclohexanediylbis[N-(carboxymethyl)glycine hydrate (1:1)
Trans-1,2-Diaminocyclohexane-N,N,N',N'-tetraacetic acid monohydrate (CDTA) is a chelating agent that has been shown to be effective in the treatment of some cancers. CDTA has been shown to inhibit the growth of tumor cells by binding to lysine residues on histones and DNA and inhibiting their acetylation. CDTA also prevents the genotoxicity induced by irradiation. CDTA can be used as an adjuvant in cancer therapy due to its ability to inhibit histone deacetylase activity. Trans-1,2-Diaminocyclohexane-N,N,N',N'-tetraacetic acid monohydrate is synthesized from two amino acids: lysine and glutamic acid. This molecule is a polymeric compound composed of cyclic molecules linked together through amide bonds. These polymers are linear chains of
Chemical properties
Technical inquiry about: 3D-FD15679 trans-1,2-Diaminocyclohexane-N,N,N',N'-tetraacetic acid monohydrate
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.